Conference Coverage

VIDEO: Advanced melanoma on brink of immunotherapy ‘revolution’


 

AT THE ASCO ANNUAL MEETING 2014

CHICAGO – Advanced melanoma therapy – a field notorious for offering patients few drugs and little chance of survival – may be on the brink of an extraordinary transformation.

"There’s truly a revolution going in the immunotherapy of melanoma," explained Dr. Steven O’Day of the Beverly Hills (Calif.) Cancer Center.

In a video interview at the annual meeting of the American Society for Clinical Oncology, Dr. O’Day reviews the rapid developments in melanoma treatment options and the shift from a "nuclear bomb" approach to a more-targeted "cruise missile" mindset. He also highlights the parallels between the exceptional advances made in childhood leukemia treatment and new melanoma treatments such as ipilimumab and PD-1 inhibitors, and he discusses the new drugs’ ability to overcome a phenomenon that often defeats chemotherapy: cancer cell resistance.

function runABTest(_videoIDs) { var rand = Math.floor(Math.random() * _videoIDs.length); return _videoIDs[rand]; } function delvePlayerCallback(playerId, eventName, data) { if (eventName == 'onPlayerLoad') DelvePlayer.doLoadMedia(runABTest (['32effa5913274f2c95e538a17315f137','7504d03ff06d490f8db8b6f4cb484228'])); } LimelightPlayerUtil.initEmbed('limelight_player_156792');

Recommended Reading

Single-fraction radiation therapy showed promise in metastatic Merkel cell carcinoma
MDedge Hematology and Oncology
Infrared detector distinguished malignant and benign skin lesions
MDedge Hematology and Oncology
Topical tazarotene did not improve response to imiquimod 5% in lentigo maligna
MDedge Hematology and Oncology
Nonmelanoma skin cancer linked to increased fracture risk in postmenopausal women
MDedge Hematology and Oncology
Drugs approved in 2013
MDedge Hematology and Oncology
Consumer Reports: Sunscreen SPF claims largely inaccurate
MDedge Hematology and Oncology
ASCO 2014: Dr. Jeffrey A. Sosman gives his top picks in melanoma research
MDedge Hematology and Oncology
High rate of durable responses to pembrolizumab in metastatic melanoma
MDedge Hematology and Oncology
‘Unprecedented’ overall survival of metastatic melanoma
MDedge Hematology and Oncology
VIDEO: Pembrolizumab may herald new hope in advanced melanoma
MDedge Hematology and Oncology